Business
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Temple University
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Temple University.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Temple University\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Temple University\nPR Newswire\nSAN DIEGO, Feb. 13, 2020\n\n\n\nSAN DIEGO, Feb. 13, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc. (\"Kannalife\") (OTC: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Health's (NIH) National Institute on Drug Abuse (NIDA).\nThe study was performed by Kannalife and the Lewis Katz School of Medicine at Temple University (LKSOM) to assess KLS-13019, Kannalife's patented cannabidiol (CBD)-like molecule, as a potential treatment of neuropathic pain and drug dependence.\n\"KLS-13019 continues to show potential as a much-needed treatment for CIPN,\" said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. \"According to a recent study conducted by RRI, it is estimated that the total global neuropathic pain market will be worth more than $8.3 billion by 2024.\"\nThe pre-clinical grant study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN). The animal model portion of the study was conducted by Sara Jane Ward, Ph.D., Assistant Professor of Pharmacology at LKSOM. \n\"These recent study results suggest that Kannalife's proprietary CBD-like molecule is at least as effective as CBD in preventing neuropathic pain in animal models. Even fu...